# Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

> **NCT05513664** · — · UNKNOWN · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- EGFR Exon20 Insertion Mutations

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT05513664
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2023-06
- **Final completion:** 2023-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513664, "Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05513664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*